Oculis Holding AG (Oculis Holding AG) EPS (Basic) : $-1.69 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG EPS (Basic)?

Oculis Holding AG's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.50. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.69.

Oculis Holding AG's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.85.

Oculis Holding AG's EPS without NRI for the three months ended in Mar. 2024 was $-0.46. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -1.56.

During the past 3 years, the average EPS without NRI Growth Rate was -54.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Oculis Holding AG's highest 3-Year average EPS without NRI Growth Rate was -54.80% per year. The lowest was -54.80% per year. And the median was -54.80% per year.

Oculis Holding AG EPS (Basic) Historical Data

The historical data trend for Oculis Holding AG's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG EPS (Basic) Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-0.51

-0.62

-1.27

-3.43

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial							-3.86	-0.42	-0.53	-0.24	-0.50

Oculis Holding AG EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Oculis Holding AG's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-102.685	-	0)	/	29.900
	=	-3.43

Oculis Holding AG's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-18.111	-	0)	/	36.621
	=	-0.49

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.69

Oculis Holding AG (NAS:OCS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Oculis Holding AG EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (Oculis Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.